

Depression: Brain Causes - Body Consequences

A Conference organized by the Institute of Psychiatry, King's College London, 2nd and 3rd April 2007, at the Royal Society of Medicine, London, UK.


Depression cannot be described any longer as a simple disorder of the brain, but rather as a series of behavioural and biological changes that spans mind, brain, genes, body – and indeed affects both psychological and physical health. This unique conference will bring together the world leaders in research on depression, to discuss, for the first time in an interdisciplinary setting, both classical and innovative ideas to understand this devastating disorder.

Abstracts are welcome for poster presentation. Reduced fees are available for students and for standard registration before 31/12/06. Registration closes on 14/02/07.

Please go to www.iop.kcl.ac.uk/depression for further information on the speakers and the programme.

The Scientific Committee: Carmine M. Pariante (London), Robin Murray (London), David Nutt (Bristol), Randolph Nesse (Ann Arbor, Michigan), Lewis Wolpert (London).

Please note: Any conflicts of interest of Speakers and Chairs are listed at the end of this programme.



Day 1 Program, Monday 2nd of April**Registration****7:45-8.30****Welcome**

Lewis Wolpert, Robin M. Murray

8:30-8:45**Opening Lecture**

Chair: David Nutt

Charles B. Nemeroff: Is depression a disorder of the whole body?

8.45-9.30**Symposium 1 - Depression: why me?****9:30-11:00**

Chair: Lewis Wolpert, Peter McGuffin

Bernard Crespi: Is depression a maladaptation?

Terrie Moffitt: Depression - Nature or Nurture?

Randolph Nesse: Why does mood exist?

Morning Tea

11:00-11.30**Speech by the Secretary of State for Health****11.30-12:00**

Chair: Carmine M. Pariante

Rt Hon Patricia Hewitt MP

Symposium 2: Is depression an immune disorder?**12:00-13:30**

Chair: Charles B. Nemeroff, Matthew Hotopf

Robert Dantzer: Cytokines and Depression: What are the Intermediate Mechanisms?

Ted Dinan: HPA axis and cytokines: what is the link?

Andrew H. Miller: Neuropsychiatric adverse effects of interferon-alpha: do they tell us anything about depression?

Lunch Break

13:30-14:30**Symposium 3: Is depression an endocrine disorder?****14:30-16:30**

Chair: Ted Dinan, Stafford Lightman

Stephan Claes: Do stress genes cause depression?

Ian Goodyer: Does cortisol cause depression?

Jim van Os: Do genes regulate our response to stress?

Elizabeth Young: PTSD and Depression: same hormones, two disorders?

Afternoon Tea

16:30-17:00**Symposium 4: Does depression have damaging effects? 17:00:19:00**

Chair: Martin Raff, Simon Wessely

Anthony Cleare: Does depression induce pain and fatigue?

Paul J Lucassen: Does depression damage the brain?

Veronica O'Keane: Does pregnancy cause depression?
Andrew Steptoe: Does depression cause coronary heart disease?

Poster Session & Canapés Reception

19:00-20:00

Day 2 Program, Tuesday, 3rd of April

Symposium 5: The anatomy of depression

8:30-10:30

Chair: David Nutt, Allan Young

Philip J Cowen: Is it just monoamines?

Helen Mayberg: The brain circuits of depression

Hamish McAllister-Williams: Can we use EEG to localise depression?

Thomas Schlaepfer: Can we use magnet fields to localise depression?

Morning Tea

10:30-11:00

Symposium 6: Can we model depression in animals?

11:00-13:00

Chair: Andrew H Miller, Kathy J. Aitchison

Peter Gass: Can we make animals resistant to depression?

Steven F. Maier: Where are vulnerability and resilience localised in the brain?

Jonathan Seckl: Can we program animals to be depressed?

Stephen J. Suomi: Can we model depression in monkeys?

Lunch Break

13:00-14:00

Symposium 7: Is bipolar different from unipolar?

14:00-16:30

Chair: Nicol Ferrier, Robin Murray

Anne Mudge: Molecular insight into mood-affecting drug action.

Mike Owen: Is it all in the genes?

Mary Phillips: Bipolar and unipolar depression: same or different brain mechanisms?

Alan Schatzberg: Does targeting the HPA axis work?

Allan Young: Bipolar and unipolar depression: what are the differences?

Closing Lecture

16:30-17.15

Chair: Robin Murray

David Nutt: How can we discover new antidepressants?

Interests in relation to one or more organisations that could be perceived as a possible conflict of interest in the context of this conference

Dr Katherine J Aitchison

She is an invited member of Advisory Boards and recipient of Consultancy fees for Johnson & Johnson, Lundbeck, Roche Diagnostics, and Bristol-Myers Squibb. Member, Bristol-Myers Squibb UK Steering group 2003 to present. Recipient of research grants from Bristol-Myers Squibb Pharmaceuticals Limited, and Johnson & Johnson Pharmaceutical Research and Development. Working with GlaxoSmithKline on a European Commission funded project. Recipient of research support from Roche Molecular Systems, Incorporated and Roche Diagnostics, UK.

Prof Stephan Claes

None declared

Dr Anthony Cleare

Has received consulting, speaking fees and sponsorship for conference attendance from Eli Lilly, speaking fees for Organon, consulting fees from Cyberonics and Pharmacia, and an unrestricted grant from GSK

Prof Philip J Cowen

He has acted as an advisor to: GlaxoSmithKline, Eli Lilly, Lundbeck, Servier, Wyeth

Prof Bernard Crespi

None declared

Prof Robert Dantzer

None declared

Prof Ted Dinan

None declared

Prof Nicol Ferrier

None declared

Dr Peter Gass

None declared

Prof Ian Goodyer

None declared

Prof Matthew Hotopf

None declared

Prof Stafford Louis Lightman

None declared

Dr Paul John Lucassen

None declared

Prof Steve F Maier

None declared

Prof Helen S Mayberg

She has a consulting agreement with Advanced Neuromodulation Systems, Inc, which has licensed her intellectual property to develop Deep Brain Stimulation for the treatment of severe depression. The terms of these arrangements have been reviewed and approved by Emory University in accordance with their conflict of interest policies.

Dr Hamish McAllister-Williams

None declared

Prof Peter McGuffin

None declared

Prof Andrew H Miller

He has served as a consultant for Schering-Plough and Centocor, and has received research funding from Janssen/Johnson and Johnson, GlaxoSmithKline, and Schering-Plough.

Prof Terrie E Moffitt

None declared

Prof Anne Mudge

None declared

Prof Robin M Murray

None declared

Prof Charles B Nemeroff

In the past three years, Dr. Nemeroff consulted to, served on the Speakers' Bureau and/or Board of Directors, has been a grant recipient, and/or owned equity in one or more of the following: Abbott Laboratories, Acadia Pharmaceuticals, American Foundation for Suicide Prevention(AFSP), American Psychiatric Institute for Research and Educations(APIRE), AstraZeneca, BMC-JR LLC, Bristol-Myers-Squibb, CeNeRx, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Entrepreneur's Fund, Forest Laboratories, George West Mental Health Foundation, GlaxoSmithKline, i3 DLN, Janssen Pharmaceutica, Lundbeck, National Alliance for Research on Schizophrenia and Depression(NARSAD), Neuronetics, NIMH, NFMH, NovaDel Pharma, Otsuka, Pfizer Pharmaceuticals, Quintiles, Reevax, UCB Pharma, Wyeth-Ayerst. Currently, Dr. Nemeroff serves on the Scientific Advisory Board for Astra-Zeneca, Johnson & Johnson, Pharma Neuroboost, Forest Laboratories , Quintiles and NARSAD. He is a grant recipient from NIH, NARSAD and AFSP. He serves on the Board of Directors of AFSP, APIRE, NovaDel Pharmaceuticals and the

George West Mental Health Foundation. He owns equity in CeNeRx and Reevax. He owns stock or stock options in Corcept, Cypress Biosciences and NovaDel.

Prof Randolph M Nesse

None declared

Prof David Nutt

He and members of his research team have received research grants speakers honoraria and consulting fees from a number of companies with interests in the treatment of depression.

Dr Veronica O'Keane

None declared

Prof Michael Owen

None declared

Dr Carmine M. Pariante

He and members of his research team have received research grants speakers honoraria and consulting fees from a number of companies with interests in the treatment of depression.

Prof Mary Phillips

None declared

Prof Martin Raff

None declared

Prof Alan F Schatzberg

He is a consultant to Eli Lilly and co-founder of Corcept Therapeutics.

Prof Thomas E. Schlaepfer

None declared

Prof Jonathan Seckl

None declared

Prof Andrew Steptoe

None declared

Prof Stephen Suomi

None declared

Prof Jim van Os

None declared

Prof Simon Wessely

None declared

Prof Lewis Wolpert

None declared

Prof Allan Young

None declared

Prof Elizabeth A Young

None declared